Novo Nordisk A/S (N1VO34 SA) stock market data APIs
R$27.6426
0.15(0.5%)
as of May 5, 2026
Try our APIs with
free plan!
Novo Nordisk A/S Financial Data Overview
Price chart is built with
Anychart
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Prev. Close
27.6426
Open
27.6707
High
27.7407
Low
27.417
52 wk Range
22.9-55.4118
Market Cap
981 200 M
P/E Ratio
12.3482
Shares Outstanding
26 875 M
Revenue
309 064 M
Dividends (Yield)
0.425
Beta
0.348
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novo Nordisk A/S data using free add-ons & libraries
Get Novo Nordisk A/S Fundamental Data
Novo Nordisk A/S Fundamental data includes:
- Net Revenue: 309 064 M
- EBITDA: 153 295 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novo Nordisk A/S News
New
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
Novo Nordisk A/S Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026 Financial performance Q1 2026 reported sales increased by 32% at CER, positively im...
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Eli Lilly and Company LLY gained the much-anticipated FDA approval for its once-daily oral GLP-1 pill, Foundayo (orforglipron), for treating obesity in early April. Foundayo shipments began soon afte...
Lexaria Updates Progress on Human Study #7
KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pil...
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
BOSTON, May 5, 2026 /PRNewswire/ -- Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded wit...
Get Novo Nordisk A/S fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
